About electrocore inc - ECOR
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P. Errico, Steven M. Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Rockaway, NJ.
ECOR At a Glance
electroCore, Inc.
200 Forge Way
Rockaway, New Jersey 07866
| Phone | 1-973-290-0097 | Revenue | 32.03M | |
| Industry | Medical Specialties | Net Income | -13,966,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 27.202% | |
| Fiscal Year-end | 12 / 2026 | Employees | 83 | |
| View SEC Filings |
ECOR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.188 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.122 |
| Enterprise Value to Sales | 1.119 |
| Total Debt to Enterprise Value | 0.262 |
ECOR Efficiency
| Revenue/Employee | 385,927.711 |
| Income Per Employee | -168,265.06 |
| Receivables Turnover | 31.19 |
| Total Asset Turnover | 1.556 |
ECOR Liquidity
| Current Ratio | 1.381 |
| Quick Ratio | 1.237 |
| Cash Ratio | 1.023 |
ECOR Profitability
| Gross Margin | 86.751 |
| Operating Margin | -41.062 |
| Pretax Margin | -43.591 |
| Net Margin | -43.60 |
| Return on Assets | -67.837 |
| Return on Equity | -478.698 |
| Return on Total Capital | -181.518 |
| Return on Invested Capital | -149.866 |
ECOR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 122.212 |
| Total Debt to Total Assets | 48.08 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 117.338 |